Weaning Off Zepbound (Tirzepatide)
There is no established tapering protocol for discontinuing tirzepatide (Zepbound), and current guidelines do not recommend gradual dose reduction when stopping the medication—you can simply discontinue it abruptly without medical risk.
Key Clinical Guidance
The most recent AACE consensus statement (2025) addresses discontinuation of GLP-1 receptor agonist-based medications including tirzepatide, but provides guidance only for restarting therapy, not for tapering off 1. The guideline explicitly states: "Patients should be counseled that if they discontinue or pause treatment for a length of time, they will need to restart at a low dose and titrate up to enable the body time to acclimate to the medication" 1.
What This Means Clinically
- No taper required: Unlike medications such as corticosteroids or benzodiazepines, tirzepatide does not require gradual dose reduction
- Abrupt discontinuation is safe: There are no withdrawal symptoms or rebound effects that necessitate tapering
- Weight regain is expected: This is a consequence of stopping treatment, not a withdrawal phenomenon
Critical Considerations When Stopping Tirzepatide
Expected Outcomes After Discontinuation
Weight regain will occur in most patients. Clinical trial data demonstrate that discontinuing tirzepatide leads to substantial weight regain, as obesity is a chronic disease requiring ongoing management 1. This is not a side effect of stopping—it reflects the underlying disease process reasserting itself.
If Restarting Is Planned
You must restart at the lowest dose (2.5 mg weekly) and titrate up monthly, regardless of the previous maintenance dose 1. This is essential because:
- The body loses tolerance to the medication during the discontinuation period
- Starting at higher doses after a break significantly increases gastrointestinal side effects (nausea, vomiting, diarrhea)
- The standard titration schedule is: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with monthly increases 1
Monitoring After Discontinuation
While no specific monitoring is required for the discontinuation itself, consider the following:
Metabolic Parameters
- Blood glucose: Particularly important in patients with type 2 diabetes, as glycemic control will deteriorate after stopping 1
- Blood pressure and lipids: Cardiometabolic improvements achieved during treatment may reverse 1
- Weight: Regular monitoring to assess trajectory of weight regain
Comorbid Conditions
If tirzepatide was treating specific conditions beyond obesity, anticipate recurrence:
- Obstructive sleep apnea symptoms may worsen 1
- Cardiovascular risk factors may deteriorate 1
- Prediabetes may progress to type 2 diabetes 1
Common Pitfalls to Avoid
Do not attempt a gradual taper thinking it will prevent weight regain—it won't. Weight regain is related to the absence of the medication's metabolic effects, not to how quickly you stop it.
Do not restart at the previous maintenance dose after any significant break (more than a few weeks). This is the most common error and leads to severe gastrointestinal distress 1.
Do not assume patients understand weight regain is expected. Explicitly counsel patients that obesity is a chronic disease, and stopping medication will result in weight regain in most cases, similar to stopping blood pressure medication causing blood pressure to rise again.
Alternative Management Strategies
If discontinuation is due to side effects, cost, or access issues rather than patient preference:
- Consider dose reduction to a tolerable level rather than complete discontinuation
- Evaluate switching to alternative GLP-1 RA if specific side effects are problematic
- Intensify lifestyle interventions before discontinuation to optimize weight maintenance
- Consider combination therapy with other anti-obesity medications if appropriate 2
The evidence consistently demonstrates that obesity pharmacotherapy, including tirzepatide, requires long-term or indefinite treatment for sustained benefit 2, 1. Discontinuation should be a deliberate decision made with full understanding of expected outcomes.